Hims Peptide Therapy: An Objective Review

Who Is Hims?

Hims & Hers Health, Inc. is a publicly traded telehealth company (NYSE: HIMS) founded in 2017. The platform connects patients with licensed healthcare providers for virtual consultations and, if appropriate, prescriptions that are filled and shipped directly. The company initially focused on men's health categories — hair loss, sexual health, skincare — and has since expanded into weight management, mental health, and peptide therapy.

The company operates in all 50 U.S. states and has built a large subscriber base through its direct-to-consumer model. Peptide therapy represents a newer vertical for Hims, and its significance grew substantially with the mid-2026 compounding facility acquisition.

The Menlo Park Compounding Facility Acquisition

In July 2026, Hims acquired a compounding facility in Menlo Park, California, a move reported by the Wall Street Journal. Compounding pharmacies produce customized medications — including peptides — that are not commercially available as FDA-approved finished products. By bringing compounding in-house, Hims gains more control over its supply chain, quality oversight, and production timelines.

This acquisition is notable for several reasons:

• Supply chain control: rather than relying on third-party compounding pharmacies, Hims can now oversee peptide production directly, which in theory allows tighter quality control and faster fulfillment.
• Regulatory positioning: owning a compounding facility means Hims must comply with state pharmacy board regulations, FDA oversight under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, and applicable cGMP (current Good Manufacturing Practice) standards — all of which are verifiable by consumers.
• Market signal: vertical integration suggests Hims views peptide therapy as a long-term business line, not a short-term experiment.

Dr. Anant Vinjamoori, Hims's Chief Medical Officer, has publicly stated that the company supports FDA review of peptides and aims to operate within the regulatory framework rather than around it. That stated position is worth noting, though consumers should evaluate actions alongside statements over time.

What Peptides Does Hims Offer?

Hims has not published a comprehensive public catalog of every peptide available through its platform, and specific offerings may change as the regulatory environment evolves. Rather than list specific products or prices that may be outdated by the time you read this, we recommend checking hims.com directly for current offerings.

What is publicly known: Hims positions its peptide therapy within a clinician-supervised model, meaning a licensed provider evaluates whether a given peptide is appropriate for a patient before any prescription is written. The types of peptides typically offered through telehealth platforms like Hims include those related to recovery, tissue repair, and metabolic support — categories that overlap with peptides like BPC-157 and TB-500, though we cannot confirm Hims's specific formulary without current data from their platform.

If you are researching specific peptides, our individual peptide pages cover the evidence base independent of any particular provider.

How Hims Peptide Therapy Works

The general process follows the standard telehealth consultation-to-delivery model:

1. Online consultation: a patient completes a health questionnaire and connects with a licensed healthcare provider through the Hims platform. This may be synchronous (video or phone) or asynchronous (message-based), depending on the state and the provider's discretion.
2. Clinical evaluation: the provider reviews the patient's health history, current medications, and goals to determine whether peptide therapy is appropriate. Not every consultation results in a prescription — a responsible provider should decline to prescribe if the clinical picture does not support it.
3. Prescription and compounding: if a prescription is written, the order goes to a compounding pharmacy — now potentially Hims's own Menlo Park facility — where the peptide is prepared according to the prescription specifications.
4. Delivery: the compounded peptide is shipped directly to the patient with instructions for use, storage, and follow-up.

This model is not unique to Hims — it is the standard for legitimate telehealth peptide providers. What varies between platforms is the rigor of the clinical evaluation, the quality of the compounding source, and the follow-up care provided after the initial prescription.

Hims vs Other Telehealth Peptide Providers

Hims is not the only telehealth platform offering peptide therapy. Several companies operate in this space, and the market has grown substantially as consumer interest in peptides has increased. Rather than fabricate a comparison of specific competitors — whose offerings, prices, and practices change frequently — the table below outlines the factors that matter when evaluating any telehealth peptide provider, including Hims.

Key takeaway: no single telehealth platform is automatically the best choice. The right provider depends on which peptides you need, your state's regulations, cost, and how comfortable you are with the clinical evaluation process. Use the factors above to evaluate any provider, including Hims, rather than relying on marketing claims alone.

Legitimacy Signals: How to Evaluate Hims (or Any Provider)

The peptide market includes both legitimate medical providers and gray-market sellers with no clinical oversight. When evaluating Hims or any telehealth peptide platform, these are the legitimacy signals that matter:

• Licensed physicians or nurse practitioners: every prescription should come from a provider licensed in your state. Hims uses licensed providers, which is verifiable through state medical board databases.
• Prescription requirement: legitimate peptide therapy requires a clinical evaluation and a prescription. If a platform sells peptides without any medical consultation, that is a red flag — see are peptides legal for more on the legal framework.
• Compounding pharmacy credentials: the pharmacy producing the peptides should be registered with the relevant state board of pharmacy and, if operating as an outsourcing facility, registered with the FDA under Section 503B. Hims's Menlo Park facility should be verifiable through these channels.
• Corporate accountability: as a publicly traded company, Hims is subject to SEC reporting requirements, quarterly earnings disclosures, and public scrutiny that privately held competitors may not face. This does not guarantee quality, but it does create accountability mechanisms.
• CMO and medical leadership: Hims's Chief Medical Officer, Dr. Anant Vinjamoori, has made public statements supporting FDA review of peptides. Visible medical leadership with named, credentialed individuals is a positive signal compared to platforms where no medical leadership is identifiable.

None of these signals, individually or together, guarantee a good clinical outcome. They are necessary conditions for legitimacy, not sufficient ones. Your own due diligence — including verifying provider credentials and asking for certificates of analysis on compounded products — remains important.

What the July 2026 FDA Committee Vote Means for Hims

In July 2026, an FDA advisory committee voted on recommendations related to certain peptides and their regulatory classification. The details of these votes and their downstream effects on compounding are still unfolding, but the broad implications for Hims and similar providers are worth understanding.

The FDA's regulatory stance on compounded peptides has been tightening. The agency has increased scrutiny of compounding pharmacies, particularly those producing copies of commercially available FDA-approved drugs. For peptides that do not have an FDA-approved commercial equivalent, compounding remains a legal pathway under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act — but the boundaries are shifting.

For Hims specifically, several factors are relevant:

• In-house compounding as a hedge: by owning its own facility, Hims has more control over compliance and can adapt more quickly to regulatory changes than platforms relying on third-party pharmacies.
• Public support for FDA oversight: Dr. Vinjamoori's stated position supporting FDA review suggests Hims is positioning itself to work within whatever regulatory framework emerges, rather than against it.
• Uncertainty remains: FDA advisory committee votes are recommendations, not final rules. The actual regulatory impact will depend on subsequent FDA rulemaking, enforcement actions, and potential legal challenges from the compounding industry.

For patients, the practical takeaway is that the peptide landscape is in flux. A provider's willingness to operate transparently within the regulatory framework — rather than rushing to sell peptides before the rules catch up — is a meaningful differentiator. For the broader legal context, see our peptide legality FAQ.

Limitations and Things to Watch For

An objective review should include what we do not know or cannot verify, not just what looks good on paper:

• Clinical depth of telehealth consultations: telehealth platforms vary in how thoroughly providers evaluate patients. A brief asynchronous questionnaire is not the same as an in-depth clinical workup. If your peptide therapy needs are complex, an in-person evaluation with a specialist may be more appropriate than any telehealth platform.
• Compounding quality is hard to verify externally: even with an in-house facility, consumers cannot independently audit production processes. Ask for certificates of analysis (COAs) for any compounded product you receive, and verify that the facility is in good standing with its state board of pharmacy.
• Evolving product availability: what Hims offers today may change as FDA regulations shift. Peptides that are available now could be removed from their formulary if regulatory conditions change.
• Marketing vs clinical reality: Hims is a consumer brand with a marketing operation. Not everything on a marketing page reflects the nuance of clinical evidence. Evaluate peptide claims against the research literature, not against any provider's sales copy — our individual peptide pages (BPC-157, TB-500, and others) cover the evidence base independently.
• Cost transparency: telehealth peptide therapy can be expensive, and costs vary by peptide, dosage, and subscription model. Ensure you understand the full cost structure — including consultation fees, medication costs, and any recurring charges — before committing.

The Bottom Line

Hims has made a credible move into peptide therapy. The Menlo Park compounding facility acquisition, public medical leadership, and prescription-based model are all positive legitimacy signals. The company's status as a publicly traded entity adds a layer of accountability that many competitors in the peptide space lack.

That said, this is not an endorsement. Telehealth consultations have inherent limitations compared to in-person care, the peptide regulatory landscape is actively shifting, and no provider — regardless of how well capitalized — is a substitute for your own clinical judgment in partnership with a trusted physician.

If you are considering peptide therapy through Hims or any other platform, start by understanding what peptides actually do and what the evidence supports. Our peptide therapy overview covers the fundamentals, and the peptide legality FAQ explains the regulatory framework. For a broader assessment of your metabolic and hormonal health, the free health assessment can help identify where to focus before committing to any specific treatment.